INCREASED SALES AND SIGNIFICANTLY IMPROVED EARNINGS
July – September · Net sales increased by 38% to SEK 4,627k (3,358k). · Comprehensive income was a loss of SEK 1,059 (loss: 6,470k). · Comprehensive income per share totaled SEK -0.02 (-0.18). · Cash flow from operating activities was SEK -3,003k (-2,698k). · Cash and cash equivalents including short-term investments amounted to SEK 6,599k (6,145k) at the end of the period. Events after the end of the period Genovis has entered into a license agreement with Life Technologies, a wholly owned subsidiary of Thermo Fisher Scientific, and is launching a unique new